Highlights

  • Cochlear Limited cut its FY26 underlying net profit guidance to AUD 290–330 million from its previously disclosed lower-end expectation of approximately AUD 435–460 million — a reduction of approximately AUD 130 million at the midpoint — citing softer-than-expected developed market sales, Middle East uncertainty, lower gross margins, cost restructuring charges, and a stronger Australian dollar.
  • Developed market cochlear implant revenue has been flat quarter-on-quarter since January in constant currency, affected by hospital capacity constraints, reduced hearing aid channel referrals, declining consumer sentiment in the US, and surgical volume constraints in Western Europe. Middle East uncertainty may require up to AUD 10 million in receivables provisioning.
  • COH shares fell AUD 61.929, or 36.876%, to AUD 106.010 on volume of 797,658 shares and a market cap of AUD 10.98 billion — one of the largest single-session declines in Cochlear's listed history — on 22 April 2026.

Cochlear (ASX:COH) shares fell AUD 61.929, or 36.876%, to AUD 106.010 on 22 April 2026, on volume of 797,658 shares with a bid-offer spread of AUD 106.000 to AUD 106.140 and market capitalisation of AUD 10.98 billion. The 36.9% single-session decline is an extraordinary re-pricing for a company of Cochlear's stature and reflects the scale and breadth of the guidance cut. The reduction of approximately AUD 130 million at the midpoint of the guidance range represents more than a one-third decline in expected annual earnings — a magnitude that justified a commensurate re-rating of the share price as investors reassessed forward earnings multiples and growth assumptions.

The Five Drivers of the Guidance Cut

Cochlear enumerated five distinct drivers of the FY26 earnings reduction in its trading update. First, second-half sales growth is now expected to be 2–6% in constant currency, compared with the much stronger trajectory implied by prior guidance, with developed market cochlear implant revenue flat in constant currency in the quarter since January. Second, the Middle East conflict introduces up to AUD 10 million in potential net profit impact from provisions for receivables due to order cancellations and delivery delay risks in the region.

Third, lower demand and the resultant reduction in Cochlear's production plan are expected to impact gross margin by approximately one percentage point due to lower overhead recoveries — an approximately AUD 20 million net profit impact. Fourth, expenses associated with the cost base reshaping programme will be recognised above the line in FY26, with an expected AUD 18–25 million net profit impact. Fifth, the stronger Australian dollar — with exchange rates revised to 71 cents AUD/USD and 61 cents AUD/EUR from 66 cents and 56 cents — carries an approximately AUD 25 million after-tax impact in the second half. Collectively these five factors reduce FY26 underlying net profit from the previously guided range to AUD 290–330 million.

Developed Markets: Structural and Cyclical Pressures Converging

The developed market softness is the primary revenue driver of the guidance reduction and reflects a convergence of structural and near-term pressures. Hospital capacity constraints have reduced near-term surgical volumes, while reduced referral activity from the hearing aid channel — which is itself experiencing declining activity — has curtailed the pipeline of new cochlear implant candidates. Consumer sentiment has reached historic lows in the US, affecting discretionary healthcare decisions in the adults and seniors segment.

In Western Europe, the UK and Germany face growing surgical waiting lists due to constrained volumes, while industrial action in Italy and Spain has further restricted surgical throughput. The US was broadly in line with expectations through mid-February but saw volume declines in March. Despite these near-term dynamics, Cochlear's CEO Dig Howitt noted very positive customer feedback on the newly launched Nucleus Nexa System and improving market share following contracting completion for the new system.

Cost Base Reshaping and Medium-Term Confidence

Cochlear announced an acceleration of its cost base reshaping programme, which aims to reallocate resources toward strengthening referral pathways and commercial execution in the adults and seniors segment, continuing investment in new products and digital capability, and driving scale across support activities. The AUD 18–25 million charge associated with this programme will be taken above the line in FY26. Management signalled confidence that the restructuring will create a more flexible, lower cost-to-serve foundation for sustained longer-term growth.

Cochlear reaffirmed its confidence in its long-term growth strategy and innovation pipeline, noting that two clinical studies for regulatory approval of a drug-eluting electrode are fully recruited with initial results being analysed, and two studies for the totally implantable cochlear implant are underway. The company also noted strong Services revenue growth of 13% in constant currency in Q3 and improving Acoustics revenue, with Osia System and Baha 7 expansion supporting a second-half improvement.

Conclusion

Cochlear's AUD 61.93 share price decline to AUD 106.010 — a 36.876% fall on volume of 797,658 and a market cap of AUD 10.98 billion — on 22 April 2026 is the immediate market response to a guidance reduction of approximately AUD 130 million at the midpoint, driven by five compounding factors: developed market sales softness, Middle East receivables risk, lower gross margins from reduced production volumes, cost base reshaping charges, and adverse AUD appreciation. Management has simultaneously outlined an accelerated programme to reshape the cost base and reaffirmed confidence in the medium-term growth strategy, with clinical programmes advancing and market share recovering following the Nucleus Nexa System launch.